Abivax to be Added to Nasdaq Biotechnology Index

Core Viewpoint - Abivax SA will be added to the Nasdaq Biotechnology Index effective December 22, 2025, marking a significant milestone for the company and enhancing its visibility in the global biotechnology community [2][3]. Company Overview - Abivax is a clinical-stage biotechnology company focused on developing therapeutics that stabilize the immune response in patients with chronic inflammatory diseases [4]. - The company's lead drug candidate, obefazimod (ABX464), is currently in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis [4]. Nasdaq Biotechnology Index (NBI) Details - The NBI tracks the performance of biotechnology and pharmaceutical companies listed on The Nasdaq Stock Market, requiring companies to meet specific eligibility criteria such as minimum market capitalization and average daily trading volume [3]. - The index is evaluated annually in December and uses a modified capitalization-weighted methodology for its calculations [3].